Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes.

Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

ngredients of our daily diet – including caffeine – can influence the resistance of bacteria to antibiotics. This has been shown in a new study by a team of researchers at the Universities of Tübingen and Würzburg. They discovered bacteria such as E. coli orchestrate complex regulatory cascades to react to chemical stimuli from their direct environment which can influence the effectiveness of antimicrobial drugs.

Rewriting the transcript to heal diseases - 29/01/2026

Therapy involving the umlauts of the genetic alphabet

tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

Mosses for pharmaceutical production - 16/09/2020

Factor H as a therapeutic option for viral diseases - including COVID-19

The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

An international research team has deciphered a mechanism of evolutionary arms race in human cells. The findings provide insights into how mobile elements in DNA hijack cellular functions – and how cells can defend themselves against this in order to prevent conditions such as tumour formation or chronic inflammation.

The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defence and antiviral drugs by becoming "latent". In this state, they are largely invisible and unassailable. As long as these dormant viruses persist, there is no cure for HIV/AIDS. However, researchers at Ulm University Hospital have discovered a new way to reactivate latent HI viruses.

Heidelberg University scientists are to receive three ERC Synergy Grants – three highly endowed grants of the European Research Council – for pioneering research projects by several teams working in collaboration.

Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.

Cluster of the future - 25/11/2021

nanodiagBW: using nanopores to create completely new diagnostic possibilities

Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.

KyooBe Tech GmbH - 08/10/2020

Next generation vaccine production

For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

Predicting the success of cancer treatment - 20/06/2023

Focusing on gut microbiome for CAR T-cell therapy

Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.

With the goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In pursuit of the artificial cell, a research team has cleared a crucial hurdle. Using the new RNA origami technique, they succeeded in producing nanotubes that fold into cytoskeleton-like structures.

The spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a basic requirement for producing proteins. Researchers at the Heidelberg University Biochemistry Center (BZH) have succeeded for the first time in depicting a faultily “blocked” spliceosome at high resolution and reconstructing how it is recognized and eliminated in the cell.

Article - 04/02/2020

Medicine from the blue blood of marine snails

A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.

Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.

Gene regulation as a starting point for cancer therapies - 02/12/2021

New investigation method for deciphering complex epigenetic networks

The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

Article - 29/01/2019

Targeted RNA editing with the body’s own enzyme activity

Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…

The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

Dossier - 02/06/2014

Bioanalysis techniques for the characterization of biological material

Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind…

Article - 26/07/2019

New test assay leads to discovery of new influenza virus infection route

Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…

ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.